MedTrace Logo

Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)

NCT01306578 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2011-03-02

No results posted yet for this study

Summary

Comparing whether intravenous immune globulin or plasma exchange is superior in treating mechanically ventilated children with Guillain Barre syndrome.

Conditions

  • Guillain Barre Syndrome

Interventions

DRUG

IVIG

Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days

PROCEDURE

Plasma Exchange

Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days

Sponsors & Collaborators

  • Mansoura University Children Hospital

    lead OTHER

Principal Investigators

  • Mohammed A El-Bayoumi, MD, FRCPCH · Head of PICU, Mansoura University Children Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
18 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-12-31
Completion
2010-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01306578 on ClinicalTrials.gov